Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02522468 · ClinicalTrials.gov registry record · NA
A Trial of RSL Versus WL for Malignant Breast Disease
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT02522468 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 400 participants.
The verdict
NCT02522468, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this randomized trial is to determine the superiority of utilizing radioactive seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable malignant lesions in patients undergoing breast conservation surgery (BCS).
Interventions
- PROCEDURE Radioactive Seed Localization
- PROCEDURE Wire Localization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2015-07-24 |
| Est. Completion | 2021-02-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02522468
The ClinicalTrials.gov registry entry for NCT02522468 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radioactive Seed Localization is the first listed.
NCT02522468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02522468 about?
NCT02522468 is a clinical study titled "A Trial of RSL Versus WL for Malignant Breast Disease". The purpose of this randomized trial is to determine the superiority of utilizing radioactive seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable malignant lesions in patients undergoing breast conservation surgery (BCS).
What is the current status of trial NCT02522468?
This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2015-07-24. Estimated completion is 2021-02-23.
What interventions are being tested in trial NCT02522468?
The interventions under investigation include: Radioactive Seed Localization (PROCEDURE), Wire Localization (PROCEDURE).
Who is sponsoring clinical trial NCT02522468?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.